Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Intra-Cellular Therapies, Inc. (ITCI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Quarterly results |
| 08/09/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 11/09/2021 |
8-K
| Quarterly results |
| 05/10/2021 |
8-K
| Quarterly results |
| 02/25/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/10/2020 |
8-K
| Quarterly results |
| 05/07/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 11/05/2019 |
8-K
| Quarterly results |
| 08/07/2019 |
8-K
| Quarterly results |
| 05/08/2019 |
8-K
| Quarterly results |
| 02/27/2019 |
8-K
| Quarterly results |
| 11/07/2018 |
8-K
| Quarterly results |
| 08/02/2018 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2018 Financial Results NEW YORK, August 2, 2018 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today provided a corporate update and announced its financial results for the second quarter ended June 30, 2018. “In the first half of 2018, we made great progress advancing our development programs and as we continue to build our team, we are pleased with the progress we have made in our activities to prepare for the commercialization of lumateperone,” said Dr. Sharon Mates, Chairman and CEO of ITCI. “We are excited about our prospects for the remainder of the year as we expect to complete our New Drug App..." |
|
| 05/03/2018 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports First Quarter 2018 Financial Results and Provides Corporate Update NEW YORK, May 3, 2018 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2018 and provided a corporate update. First Quarter 2018 Financial Results Intra-Cellular Therapies reported a net loss of $35.5 million, or $0.65 per share , for the first quarter of 2018 compared to a net loss of $26.9 million, or $0.62 per share , for the first quarter of 2017. Research and development expenses for the first quarter of 2018 were $30.7 million, compared to $21.5 million for the first quarter of 2017. The increase for t..." |
|
| 03/01/2018 |
8-K
| Quarterly results|
Docs:
|
"INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE NEW YORK, March 1, 2018 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2017, and provided a corporate update. Selected Fourth Quarter and Year End 2017 Financial Results Intra-Cellular Therapies reported a net loss of $30.2 million, or $0.56 per share , for the fourth quarter of 2017 compared to a net loss of $27.5 million, or $0.64 per share , for the fourth quarter of 2016. The Company reported a net loss of $97.8 million, or $2.12 per share , for the full year ended December..." |
|
| 11/08/2017 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Third Quarter 2017 Financial Results and Provides Corporate Update NEW YORK, November 8, 2017 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2017, and provided a corporate update. Third Quarter 2017 Financial Results Intra-Cellular Therapies reported a net loss of $22.9 million, or $0.53 per share , for the third quarter of 2017 compared to a net loss of $30.3 million, or $0.70 per share , for the third quarter of 2016. Research and development expenses for the third quarter of 2017 were $18.5 million, compared to $23.9 million for the third quarter of 2016. The decr..." |
|
| 08/09/2017 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Second Quarter 2017 Financial Results and Provides Corporate Update NEW YORK, August 9, 2017 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the second quarter ended June 30, 2017, and provided a corporate update. Second Quarter 2017 Financial Results Intra-Cellular Therapies reported a net loss of $17.8 million, or $0.41 per share , for the second quarter of 2017 compared to a net loss of $30.8 million, or $0.71 per share , for the second quarter of 2016. Research and development expenses for the second quarter of 2017 were $12.5 million, compared to $25.3 million for the second quarter of 2016. The decr..." |
|
| 05/10/2017 |
8-K
| Form 8-K - Current report |
| 03/01/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 08/04/2016 |
8-K
| Form 8-K - Current report |
| 04/28/2016 |
8-K
| Form 8-K - Current report |
| 02/25/2016 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2015 Financial Results and Provides Corporate Update NEW YORK, February 25, 2016/GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015, and provided a corporate update. Selected Fourth Quarter and Year End 2015 Financial Results Intra-Cellular Therapies reported a net loss of $28.8 million, or $0.67 per share , for the fourth quarter of 2015 compared to a net loss of $15.2 million, or $0.52 per share , for the fourth quarter of 2014. The Company reported a net loss of $104.8 million, or $2.91 per share , for the full year ended Dece..." |
|
| 11/05/2015 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Third Quarter 2015 Financial Results and Provides Corporate Update NEW YORK, November 5, 2015 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the quarter ended September 30, 2015, and provided a corporate update. Third Quarter 2015 Financial Results Intra-Cellular Therapies reported a net loss of $32.2 million, or $ per share , for the third quarter of 2015 compared to a net loss of $6.4 million, or $ per share , for the third quarter of 2014. Research and development expenses for the third quarter of 2015 were $28.5 million, compared to $4.0 million for the third quarter of 2014. The increase is primaril..." |
|
| 08/05/2015 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Second Quarter 2015 Financial Results and Provides Corporate Update NEW YORK, August 5, 2015 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the quarter ended June 30, 2015, and provided a corporate update. Second Quarter 2015 Financial Results Intra-Cellular Therapies reported a net loss of $21.5 million, or $ per share , for the second quarter of 2015 compared to a net loss of $4.5 million, or $ per share , for the second quarter of 2014. Research and development expenses for the second quarter of 2015 were $17.8 million, compared to $2.7 million for the second quarter of 2014. The increase is primarily..." |
|
| 04/30/2015 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports First Quarter 2015 Financial Results and Provides Corporate Update NEW YORK, April 30, 2015 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the quarter ended March 31, 2015, and provided a corporate update. First Quarter 2015 Financial Results Intra-Cellular Therapies reported a net loss of $22.3 million, or $ per share , for the first quarter of 2015 compared to a net loss of $4.5 million, or $ per share , for the first quarter of 2014. Research and development expenses for the first quarter of 2015 were $18.6 million, compared to $2.8 million for the first quarter of 2014. The increase is due primarily ..." |
|
| 03/12/2015 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Announces Closing of $130 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares",
"Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2014 Financial Results and Provides Corporate Update NEW YORK, March 12, 2015 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2014, and provided a corporate update. Selected Fourth Quarter and Year End 2014 Financial Results The Company reported a net loss of $15.2 million, or $ per share , for the fourth quarter of 2014 compared with a net loss of $8.0 million, or $ per share , for the fourth quarter of 2013. The Company reported a net loss of $30.7 million, or $ per share , for the full year ended December 31, 2014 compared with..." |
|
| 11/03/2014 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports Third Quarter 2014 Financial Results and Provides Corporate Update NEW YORK, November 03, 2014 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2014, and provided a corporate update. Selected Third Quarter 2014 Financial Results The Company reported a net loss of $6.4 million, or $ per share , for the third quarter of 2014 compared with a net loss of $4.9 million, or $ per share , for the third quarter of 2013. Research and development expenses for the third quarter of 2014 were $4.0 million, compared to $4.2 million for the third quarter of 2013. The decrease of $0.2 ..." |
|
| 08/12/2014 |
8-K
| Quarterly results |
| 05/05/2014 |
8-K
| Quarterly results|
Docs:
|
"Intra-Cellular Therapies Reports First Quarter 2014 Financial Results NEW YORK, May 5, 2014 /GLOBE NEWSWIRE/ — Intra-Cellular Therapies, Inc. , a biopharmaceutical company focused on the development of therapeutics for central nervous system disorders, today announced its financial results for the first quarter ended March 31, 2014, and provided a corporate update. First Quarter 2014 Financial Results The Company reported a net loss of $4.5 million, or $ per share , for the first quarter of 2014 compared with a net loss of $5.6 million, or $ per share , for the first quarter of 2013. Research and development expenses for the first quarter of 2014 were $2.8 million, compared to $5.0 million for the first quarter of 2013. The decrease is due almost exclusively to costs associated with outsid..." |
|
|
|